Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Phase 2 Completed 63 enrolled Laboratorios Leti, S.L.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerance of a rush build up administration of Depigoid forte pollen and the first maintenance dose administered 4 weeks later.

Timeline

Start: 2012-11
Primary completion: 2013-03
Completion: 2013-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Depigoid	Other / unclassified	0.5 ml	—

Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).

Summary

Timeline

Drugs

Indications